The order streamlines FDA, EPA, and Army Corps regulations and permits for domestic pharma manufacturing, aiming to accelerate plant construction. It also seeks to improve foreign facility inspections. This EO prioritizes faster US medicine production via regulatory cuts at agencies like FDA & EPA. It bets deregulation boosts supply chains. However, it risks compromising safety/environmental checks and doesn't address broader economic factors like labor costs or the core issue of medicine affordability for patients, focusing only on production location.